Dr Lal PathLabs Ltd., a leading diagnostic service provider, has officially announced its international expansion into the United Arab Emirates through the incorporation of its wholly owned subsidiary, Dr Lal PathLabs FZCO, in Dubai.
The company secured its Certificate of Incorporation and operating license from the Dubai Multi Commodities Centre (DMCC) authority on June 12, 2026. This milestone follows the strategic framework and structural approval granted by the parent company’s Board of Directors on April 30, 2026.
To fuel this regional growth, Dr Lal PathLabs has subscribed to 100% of the share capital in the new entity, reflecting a total cash investment of AED 1,91,35,000 (approximately ₹4.35 crore). Operating within the diagnostic services sector, Dr Lal PathLabs FZCO will serve as the core vehicle for the brand’s broader expansion across the Gulf Cooperation Council (GCC) region.
The subsidiary is mandated to drive clinical laboratory activities, execute strategic healthcare investments, and explore international growth via acquisitions, commercial tie-ups, and joint ventures. By establishing a permanent corporate hub in Dubai, the company aims to tap into the high-income UAE healthcare market and cater to a large expatriate population already familiar with the legacy brand.
While the entity is currently setting up its operational framework, the move aligns with the parent company’s long-term global growth strategy.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
